Longwood Fund is a venture capital firm that focuses on creating and investing in early-stage, science-based companies within the healthcare, pharmaceutical, and biotechnology sectors. Their strategy involves actively co-founding companies, often taking operational leadership roles, and providing hands-on support to accelerate the development of novel therapies for unmet medical needs.
100% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (1 deals in the last 12 months vs 3 prior). Their most common stage is series-a (60% of deals). Average disclosed round size is $84.6M (across 10 rounds with reported amounts).
Portfolio
10
Fund Size
$650M
Top Stage
Series A
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
10 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Mediar Therapeutics, Inc. | Series B | $76M | Jan 2026 |
 Solu Therapeutics | Series A | $41M | Apr 2025 |
 Evommune, Inc. | Series C | $115M | Oct 2024 |
 BridgeBio Oncology Therapeutics (BBOT) | Growth | $200M | May 2024 |
 Tome Biosciences | Series B | $213M | Dec 2023 |
 Interius BioTherapeutics | Series A | $76M | May 2021 |
| IImmuneID | Series A | $17M | Feb 2021 |
 Werewolf Therapeutics | Series A | $56M | Nov 2019 |
 Pyxis Oncology | Series A | $22M | Jul 2019 |
 Sitryx Therapeutics | Series A | $30M | Oct 2018 |
Top Co-Investors
Cormorant Asset Management2 shared
RA Capital Management2 shared
Agent Capital2 shared
Amplitude Ventures2 shared
Alexandria Venture Investments2 shared
GV (Google Ventures)2 shared
ARCH Venture Partners2 shared
Bain Capital Life Sciences1 shared
Pfizer Ventures1 shared
Logos Capital1 shared
Osage University Partners1 shared
Knollwood1 shared
BrightEdge1 shared
MPM Capital1 shared
UPMC Enterprises1 shared
Eli Lilly and Company1 shared
Pappas Capital1 shared
DCVC1 shared
Astellas Venture Management1 shared
Leaps by Bayer1 shared
Last updated: 16 April 2026